Stifel analyst Annabel Samimy raised the firm’s price target on Supernus (SUPN) to $55 from $50 and keeps a Hold rating on the shares as part of a 2026 outlook note for the analyst’s Biopharma coverage.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus Pharmaceuticals: Strategic Growth, Clinical Advances, and Strong Financial Synergies Drive Buy Rating
- Supernus management to meet virtually with Cantor Fitzgerald
- Bank of America Highlights Five Stocks It Says Still Offer Clear Upside in 2025
- Supernus Pharmaceuticals’ Earnings Call: Growth Amid Challenges
- Supernus Pharmaceuticals Reports Strong Q3 2025 Growth